Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system

Cancer Biology and Therapy

Volumn 4, Issue 11, 2005, Pages 1203-1210

  Stoff Khalili, Mariam A ^a,d   Stoff, Alexander ^a,e   Rivera, Angel A ^a   Mathis, J Michael ^f   Everts, Maaike ^a   Wang, Minghui ^a   Kawakami, Yosuke ^a   Waehler, Reinhard ^a   Mathews, Quiana L ^a   Yamamoto, Masato ^a   Rocconi, Rodney P ^b   Siegal, Gene P ^c   Richter, Dirk F ^e   Dall, Peter ^d   Zhu, Zeng B ^a   Curiel, David T ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e Dreifaltigkeits Hospital   (Germany)

^f LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Ad5 3; Adenovirus; Breast cancer; Fiber modification; Gene therapy; Model; Transductional targeting

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 7 HYDROXYSTAUROSPORINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; HUMAN;

EID: 33644648085     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.11.2084     Document Type: Article

References (49)

1. Lacey Jr JV, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 2002; 39:82-8.
2. Chen L, Chen D, Manome Y, Dong Y, Fine HA and Kufe DW. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest 1995; 96:2775-82.
3. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC and Jensen RA. Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996; 12:298-302.
4. Im SA, Kim JS, Gomez-Manzano C, Fueyo J, Liu TJ, Cho MS, Seong CM, Lee SN, Hong YK and Yung WK. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer 2001; 84:1252-7.
5. Brade AM, Szmitko P, Ngo D, Liu FF and Klamut HJ. Heat-directed suicide gene therapy for breast cancer. Cancer Gene Ther 2003; 10:294-301.
6. Nettelbeck DM. Virotherapeutics: Conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs 2003; 14:577-84.
7. Gomez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer. Eur J Cancer 1999; 35:867-85.
8. Stoff-Khalili MA, Dall P, Curiel DT. From gene therapy to virotherapy for ovarian cancer. Minerva Ginecol 2004; 56:503-14.
9. Zabner J, Freimuth P, Puga A, Fabrega A and Welsh MJ. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. J Clin Invest 1997; 100:1144-9.
10. Bauerschmitz GJ, Barker SD, Hemminki A. Adenoviral gene therapy for cancer: From vectors to targeted and replication competent agents (review). Int J Oncol 2002; 21:1161-74.
11. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J and Hsieh JT. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000; 60:5031-6.
12. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 2002; 62:1063-8.
13. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP, Wang Z and Hsieh JT. Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res 1999; 59:325-30.
14. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D and Curiel DT. Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58:5738-48.
15. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N and Curiel DT. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72:9706-13.
16. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996; 14:1570-3.
17. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996; 70:6839-6846.
18. Glasgow JN, Kremer EJ, Hemminki A, Siegal GP, Douglas JT and Curiel DT. An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology 2004; 324:103-16.
19. Rein DT, Breidenbach M, Wu H, Han T, Haviv YS, Wang M, Kirby TO, Kawakami Y, Dall P, Alvarez RD and Curiel DT. Gene transfer to cervical cancer with fiber-modified adenoviruses. Int J Cancer 2004; 111:698-704.
20. Wu H, Seki T, Dmitriev I, Uil T, Kashentseva E, Han T and Curiel DT. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther 2002; 13:1647-53.
21. Wu H, Han T, Lam JT, Leath CA, Dmitriev I, Kashentseva E, Barnes MN, Alvarez RD and Curiel DT. Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy. Gene Ther 2004; 11:874-8.
22. Krumdieck C. A new instrument for the rapid preparation of tissue slices. Anal Biochem 1980; 104:118-23.
23. Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, Rots MG, Haisma HJ, Alvarez RD, Mahasreshti PJ and Curiel DT. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res 2004; 10:8697-703.
24. Olinga P, Groen K, Hof IH, De Kanter R, Koster HJ, Leeman WR, Rutten AA, Van Twillert K and Groothuis GM. Comparison of five incubation systems for rat liver slices using functional and viability parameters. J Pharmacol Toxicol Methods 1997; 38:59-69.
25. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT and Hemminki A. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5:695-704.
26. Vanderkwaak TJ, Wang M, Gomez-Navarro J, Rancourt C, Dmitriev I, Krasnykh V, Barnes M, Siegal GP, Alvarez R and Curiel DT. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999; 74:227-34.
27. Short JJ, Pereboev AV, Kawakami Y, Vasu C, Holterman MJ and Curiel DT. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 2004; 322:349-59.
28. Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, Beerli RR, Vogt L, Ruedl C, Bachmann MF, Greber UF and Hemmi S. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 2004; 78:4454-62.
29. Wickham TJ, Tzeng E, Shears LL 2nd, Roelvink PW, Li Y, Lee GM, Brough DE, Lizonova A and Kovesdi I. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71:8221-9.
30. Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, Cao Z, Alvarez RD, Curiel DT and Hemminki A. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8:449-58.
31. Wang M, Hemminki A, Siegal GP, Barnes MN, Dmitriev I, Krasnykh V, Liu B, Curiel DT and Alvarez RD. Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery. Gynecol Oncol 2005; 96:341-8.
32. Hemminki A, Wang M, Desmond RA, Strong TV, Alvarez RD and Curiel DT. Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther 2002; 13:1505-14.
33. Carson SD, Hobbs JT, Tracy SM, Chapman NM. Expression of the coxsackievirus and adenovirus receptor in cultured human umbilical vein endothelial cells: Regulation in response to cell density. J Virol 1999; 73:7077-9.
34. Spruck CH 3rd, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC and Jones PA. p16 gene in uncultured tumours. Nature 1994; 370:183-4.
35. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M and Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75:8772-80.
36. Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D and Hallden G. A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res 2005; 11:351-60.
37. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A and Curiel DT. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8:275-80.
38. Volk AL, Rivera AA, Kanerva A, Bauerschmitz G, Dmitriev I, Nettelbeck DM and Curiel DT. Enhanced adenovirus infection of melanoma cells by fiber-modification: Incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther 2003; 2:511-5.
39. Dehari H, Ito Y, Nakamura T, Kobune M, Sasaki K, Yonekura N, Kohama G and Hamada H. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther 2003; 10:75-85.
40. Seidman MA, Hogan SM, Wendland RL, Worgall S, Crystal RG and Leopold PL. Variation in adenovirus receptor expression and adenovirus vector- mediated transgene expression at defined stages of the cell cycle. Mol Ther 2001; 4:13-21.
41. Okegawa T, Pong RC, Li Y, Bergelson JM, Sagalowsky AI and Hsieh JT. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: A functional analysis of car protein structure. Cancer Res 2001; 61:6592-600.
42. Akiyama M, Thorne S, Kirn D, Roelvink PW, Einfeld DA, King CR and Wickham TJ. Ablating CAR and integrin binding in adenovirus vectors reduces nontarget organ transduction and permits sustained bloodstream persistence following intraperitoneal administration. Mol Ther 2004; 9:218-30.
43. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000; 81:2605-9.
44. Bernt KM, Ni S, Gaggar A, Li ZY, Shayakhmetov DM and Lieber A. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther 2003; 8:746-55.
45. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B and Kay MA. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71:8798-807.
46. Jessen BA, Mullins JS, De Peyster A, Stevens GJ. Assessment of hepatocytes and liver slices as in vitro test systems to predict in vivo gene expression. Toxicol Sci 2003; 75:208-22.
47. Work LM, Ritchie N, Nicklin SA, Reynolds PN and Baker AH. Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control. Gene Ther 2004; 11:1296-300.
48. Barker SD, Dmitriev IP, Nettelbeck DM, Liu B, Rivera AA, Alvarez RD, Curiel DT and Hemminki A. Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma. Gene Ther 2003; 10:1198-204.
49. Rein DT, Breidenbach M, Kirby TO, Han T, Siegal GP, Bauerschmitz GJ, Wang M, Nettelbeck DM, Tsuruta Y, Yamamoto M, Dall P, Hemminki A and Curiel DT. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 2005; 11:1327-35.